PARIS--(BUSINESS WIRE)--Sep. 30, 2019--
Regulatory News:
Abivax (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company harnessing the immune system to develop treatments for inflammatory diseases, autoimmune diseases, cancer and a functional cure for HIV, today announced its 2019 half-year financial report disclosure. This document is available in electronic version on the website of the company (www.abivax.com) and on the AMF website (www.amf-france.org).
About ABIVAX (www.abivax.com)
ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to treat ulcerative colitis and other inflammatory diseases, viral diseases and liver cancer (hepatocellular carcinoma). ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More information on the company is available at www.abivax.com/en. Follow us on Twitter @ABIVAX_
View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005677/en/
Source: ABIVAX
Abivax
Finance Department
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41
Press Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
Press Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 1 56 88 11 22
Press Relations and Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
